Melanotan II raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-07. Anything still debated is marked as such rather than presented as settled.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
ATP + Creatine → H+ + ADP + CP (Mg2+ assisted, catalyzed by creatine kinase) ADP + Pi → ATP (during anaerobic glycolysis and oxidative phosphorylation) AMP can dephosphorylate to adenosine and diffuse out of the cell; the purine nucleotide cycle may therefore also reduce the loss of adenosine from the cell since nucleosides permeate cell membranes, whereas nucleotides do not.
==== Sniper killings ==== In February 2024, an American doctor returning from the Gaza Strip wrote an op-ed in the Los Angeles Times stating that she had witnessed children being deliberately targeted by Israeli snipers, writing, "On one occasion, a handful of children, all about ages 5 to 8, were carried to the emergency room by their parents. All had single sniper shots to the head... None of these children survived." A Canadian doctor returning from a week in Gaza stated she had seen crimes against humanity, including small children "dying of hunger, bombs, sniper shots." Israeli drone footage released in March 2024 showed Israeli snipers killing an unarmed boy in Jabalia. In April 2024, doctors said they were seeing "a steady stream of children, elderly people and others who were clearly not combatants with single bullet wounds to the head or chest." Dr. Mark Perlmutter, an American doctor working in Gaza, stated Israeli snipers were targeting children, stating, "No toddler gets shot twice by mistake by the 'world's best sniper.' And they're dead-center shots." In August 2024, an American doctor returning from Gaza stated, "We had kids shot in the chest and shot in the head – in other words, clearly deliberate, clearly targeted". In October 2024, The New York Times reported compiled testimony from 44 doctors, nurses, and paramedics who treated multiple cases of preteen children with gunshot wounds to the head or chest in Gaza.
He concluded that perineurial cysts should be considered in patients with gradually worsening sacral nerve symptoms when imaging or surgery fails to reveal a herniated disc. In 1953, Dr. Isadore Tarlov published a monograph titled Sacral Nerve-Root Cysts: Another Cause of the Sciatic or Cauda Equina Syndrome, which compiled his anatomical, histological, and clinical research on perineurial cysts. The book combined scientific analysis with case studies to illustrate the symptoms, surgical techniques, and outcomes associated with sacral cysts. In Chapter 8, titled "Clinical Significance", Tarlov presented ten patient case reports documented between 1948 and 1952, four of which involved surgeries he personally performed. The remaining cases were managed by other surgeons using various techniques. Reported symptoms included pain, paresthesia, numbness (e.g., of the penis, thigh, buttocks, rectum, or vagina), urinary incontinence, and foot weakness with absent ankle reflex. Complete surgical removal of isolated cysts often led to full recovery, while patients with multiple cysts saw more limited improvement due to conservative surgical approaches. He concluded the monograph by urging increased clinical awareness of these lesions, stating that perineurial cysts may be a surgically treatable cause of sciatic and sacrococcygeal syndromes.
Sources: en.wikipedia.org
DNA was first isolated by the Swiss physician Friedrich Miescher who, in 1869, discovered a microscopic substance in the pus of discarded surgical bandages. As it resided in the nuclei of cells, he called it "nuclein". In 1878, Albrecht Kossel isolated the non-protein component of "nuclein", nucleic acid, and later isolated its five primary nucleobases. In 1909, Phoebus Levene identified the base, sugar, and phosphate nucleotide unit of RNA (then named "yeast nucleic acid"). In 1929, Levene identified deoxyribose sugar in "thymus nucleic acid" (DNA). Levene suggested that DNA consisted of a string of four nucleotide units linked together through the phosphate groups ("Tetranucleotide hypothesis"). Levene thought the chain was short and the bases repeated in a fixed order. In 1927, Nikolai Koltsov proposed that inherited traits would be inherited via a "giant hereditary molecule" made up of "two mirror strands that would replicate in a semi-conservative fashion using each strand as a template". In 1928, Frederick Griffith in his experiment discovered that traits of the "smooth" form of Pneumococcus could be transferred to the "rough" form of the same bacteria by mixing killed "smooth" bacteria with the live "rough" form. This system provided the first clear suggestion that DNA carries genetic information. In 1933, while studying virgin sea urchin eggs, Jean Brachet suggested that DNA is found in the cell nucleus and that RNA is present exclusively in the cytoplasm.
It has also been shown to possess significant neutralizing activity against gram-positive and gram-negative bacteria, with slightly higher activity against gram-positive organisms. Many plant derived compounds have demonstrated potential as therapeutic tools. In one study sugiol showed efficacy in treating Leishmania infantum, a parasite that can cause Leishmaniasis in humans. Free sugiol was able to induce cell-death in the parasitic bacteria, and when encased in cell walls obtained from yeast was able to enter a parasitized macrophage and inhibit the L. infantum within. Because sugiol has shown so many protective effects in therapeutic trials, it is likely that in plants it acts as a chemical defense agent. Sugiol present in the resins of conifers may help to protect the plant against ROS generated during metabolism, as well as against any pathogenic viruses or bacteria.
Early specimens represent birds that were pets or came from menageries. The oldest surviving bird specimens include an African grey parrot once owned by Frances Teresa Stuart (1647–1702) that was buried with its owner in London’s Westminster Abbey. Several mummified ibis and falcons have been recorded from Egyptian tombs dating from 600 to 300 BC. Bird specimens obtained from the 18th century for natural history collections were most often obtained using firearms. Shotguns with "dust" shot were preferred to reduce damage to the specimens. Today, specimens come from a variety of sources. Many (perhaps most) are salvaged from birds killed by window and communications tower strikes, domestic cats, by-catch from fisheries, die-offs from disease, vehicle strikes, and other accidental sources of mortality. However, the world's bird collections have been argued to be inadequate in documenting avian diversity, from taxonomic, geographic, and temporal perspectives, with some parts of tropical regions considered under-represented in particular museums. Underrepresented taxa continue to be actively collected by ornithologists, generally using either firearms or mist-nets. Permitting agencies oversee these activities in most countries.
Sources: en.wikipedia.org
=== Traditional coloring with three primaries === The first known case of trichromacy coloration (of 3 primaries) can be found in a work on optics by the Belgian thinker Franciscus Aguilonius in 1613, who in his "Opticorum libri sex, philosophis iuxtà ac mathematicis utiles" in Latin (Roughly, Six books of optics: useful to philosophers as well as to mathematicians), graphed the colors flavvus, rvbevs and cærvlevs (yellow, red and blue) giving rise to the intermediate colors avrevs, viridis and pvrpvrevs (orange, green and purple) and their relationship with the extremes albvs and niger (white and black). However, the idea of three primary colors is older, as Aguilonius supported the view known since the Middle Ages that the colors yellow, red, and blue were the basic or "noble" colors from which all others are derived. This model was used for printing by Jacob Christoph Le Blon in 1725 and called it Coloritto or harmony of colouring, stating that the primitive (primary) colors are yellow, red and blue, while the secondary are orange, green and purple, or violet. In 1766, Moses Harris developed an 18-color color wheel based on this model, including a wider range of colors by adding light and dark derivatives.
==== Protein metabolism ==== The liver is responsible for the mainstay of protein metabolism, synthesis as well as degradation. All plasma proteins except Gamma-globulins are synthesised in the liver. It is also responsible for a large part of amino acid synthesis. The liver plays a role in the production of clotting factors, as well as red blood cell production. Some of the proteins synthesized by the liver include coagulation factors I (fibrinogen), II (prothrombin), V, VII, VIII, IX, X, XI, XII, XIII, as well as protein C, protein S and antithrombin. The liver is a major site of production for thrombopoietin, a glycoprotein hormone that regulates the production of platelets by the bone marrow.
As of 2019, Illinois had $8.5 billion of unpaid bills and $134 billion of pension liabilities. The gas tax that funds the 2019 infrastructure plan, 38 cents per gallon and indexed to inflation, took effect on July 1, 2019. As of 2019, Illinois had one of the highest fuel taxes in the U.S. In 2024, Pritzker signed legislation eliminating the state's 1% tax on groceries, beginning January 1, 2026. In 2024, Pritzker signed a budget into law that included the creation of the state's first child tax credit, which provided up to $300 to households with children under 12 years old that made less than $60,000 annually. In 2025, the tax credit doubled to up to $600 per child.
== See also == Breast hypertrophy – Rare human disease Male bra – Pieces of clothing that fit tightly around the skinPages displaying short descriptions of redirect targets Male lactation – Production of milk in male mammals Mammoplasia – Normal or spontaneous enlargement of breasts
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.